10% Holder Coastlands Buys $806K of Pasithea Stock Over Three Sessions
KTTA sits 55% above its 52-week low of $0.281 on elevated volume (3.0× avg).
Summary
Coastlands Capital LP bought 1,667,514 Pasithea shares for $805,944 in open-market trades from November 13-17, raising its position to 5,502,549 shares just after positive PAS-004 efficacy data.
Key Events · Ownership and Investor Activity · KTTA
-
10% Holder Adds 1.67M Shares
Coastlands Capital LP acquired 1,667,514 shares for $805,944.11 in three open-market purchases between 2026-11-13 and 2026-11-17.
-
Stake Grows to 5.5M Shares
Post-transaction holdings reached 5,502,549 shares, all held indirectly through Coastlands Capital LP.
-
Purchases Priced $0.47-$0.50
The three tranches were 209,431 shares at $0.4956, 583,083 at $0.4989 and 875,000 at $0.4700 — all above today's $0.4343 quote.
-
Timed to Positive PAS-004 Data
Buying followed the 2026-11-13 release of the first efficacy data for oral PAS-004 in NF1 patients and the 2026-11-03 FDA IND clearance.
Analysis · KTTA · Life Sciences
Coastlands Capital LP put $805,944 of real money into Pasithea across three open-market purchases from November 13 to November 17, lifting its stake to 5,502,549 shares. For a company this size, that is a large commitment, and it lands right after the November 13 release of the first actual efficacy data for oral PAS-004 in NF1 patients and the November 3 FDA IND clearance. The buyer is a financial investor, not an operator, so this is a conviction bet on the data rather than a management signal — but the size and the fact that it was done at market, not through an option exercise, makes it the strongest ownership-side endorsement the stock has seen this quarter.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KTTA was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16M. The 52-week trading range was $0.28 to $2.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.